Krystal Biotech (KRYS) EBT Margin (2023 - 2026)

Krystal Biotech has reported EBT Margin for 4 years, with the latest figure at 55.43% in Q2 2026.

• EBT Margin for Q2 2026 came in at 55.43%, up 672.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 51.44% (up 446.0% YoY), and the FY2025 annual result was 48.69%, up 1587.0% from the prior year.
• EBT Margin climbed to 55.43% in Q2 2026, from 52.79% in the prior quarter.
• Over five years, EBT Margin peaked at 943.75% in Q3 2023 and troughed at 2.06% in Q1 2024.
• A 4-year average of 115.49% and a median of 48.87% in 2025 frame the typical range for EBT Margin.
• The widest annual swing landed in 2024, when EBT Margin sank 90824 bps; it then surged 4737 bps in 2025.
• A 4-year view of EBT Margin shows it stood at 25.29% in 2023, then jumped by 111 bps to 53.35% in 2024, then decreased by 11 bps to 47.74% in 2025, then rose by 16 bps to 55.43% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 55.43% in Q2 2026, 52.79% in Q1 2026, and 47.74% in Q4 2025.